{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:58:03Z","timestamp":1792137483342,"version":"4.4.0"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Continuum"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1212\/con.0000000000000407","type":"journal-article","created":{"date-parts":[[2016,12,6]],"date-time":"2016-12-06T09:31:58Z","timestamp":1481016718000},"page":"1815-1828","source":"Crossref","is-referenced-by-count":23,"title":["Toxic and Endocrine Myopathies"],"prefix":"10.1212","volume":"22","author":[{"given":"Hans D.","family":"Katzberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles D.","family":"Kassardjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"6","key":"e_1_3_1_2_2","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1212\/01.CON.0000511070.50715.ab","article-title":"Autoimmune myopathies","volume":"22","author":"Mammen AL","year":"2016","unstructured":"Mammen AL. Autoimmune myopathies. Continuum (Minneap Minn) 2016;22(6 Muscle and Neuromuscular Junction Disorders):1852\u20131870.","journal-title":"Continuum (Minneap Minn)"},{"issue":"6","key":"e_1_3_1_3_2","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jnnp.68.6.750","article-title":"Neuromuscular findings in thyroid dysfunction: a prospective clinical and electrodiagnostic study","volume":"68","author":"Duyff RF","year":"2000","unstructured":"Duyff RF Van den Bosch J Laman DM Neuromuscular findings in thyroid dysfunction: a prospective clinical and electrodiagnostic study. J Neurol Neurosurg Psychiatry 2000;68(6):750\u2013755. doi:10.1136\/jnnp.68.6.750.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"e_1_3_1_4_2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/WNP.0b013e31821c30d9","article-title":"Electrophysiologic changes in patients with untreated primary hypothyroidism","volume":"28","author":"Eslamian F","year":"2011","unstructured":"Eslamian F Bahrami A Aghamohammadzadeh N Electrophysiologic changes in patients with untreated primary hypothyroidism. J Clin Neurophysiol 2011;28(3):323\u2013328. doi:10.1097\/WNP.0b013e31821c30d9.","journal-title":"J Clin Neurophysiol"},{"issue":"1","key":"e_1_3_1_5_2","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/mus.24637","article-title":"Necrotizing myopathy caused by central hypothyroidism","volume":"52","author":"Tiniakou E","year":"2015","unstructured":"Tiniakou E Mammen AL. Necrotizing myopathy caused by central hypothyroidism. Muscle Nerve 2015;52(1):152\u2013153. doi:10.1002\/mus.24637.","journal-title":"Muscle Nerve"},{"issue":"5","key":"e_1_3_1_6_2","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2265.2007.02909.x","article-title":"Neuromuscular complications of thyrotoxicosis","volume":"67","author":"Kung AW","year":"2007","unstructured":"Kung AW. Neuromuscular complications of thyrotoxicosis. Clin Endocrinol (Oxf) 2007;67(5):645\u2013650. doi:10.1111\/j.1365-2265.2007.02909.x.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"e_1_3_1_7_2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1089\/thy.1992.2.229","article-title":"Immunosuppressive treatment of Graves\u2019 ophthalmopathy","volume":"2","author":"Wiersinga WM","year":"1992","unstructured":"Wiersinga WM. Immunosuppressive treatment of Graves\u2019 ophthalmopathy. Thyroid 1992;2(3):229\u2013233. doi:10.1089\/thy.1992.2.229.","journal-title":"Thyroid"},{"issue":"11","key":"e_1_3_1_8_2","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/nrendo.2011.58","article-title":"Novel etiopathophysiological aspects of thyrotoxic periodic paralysis","volume":"7","author":"Maciel RM","year":"2011","unstructured":"Maciel RM Lindsey SC Dias da Silva MR. Novel etiopathophysiological aspects of thyrotoxic periodic paralysis. Nat Rev Endocrinol 2011;7(11):657\u2013667. doi:10.1038\/nrendo.2011.58.","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"e_1_3_1_9_2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1530\/EJE-13-0381","article-title":"A 10-year analysis of thyrotoxic periodic paralysis in 135 patients: focus on symptomatology and precipitants","volume":"169","author":"Chang CC","year":"2013","unstructured":"Chang CC Cheng CJ Sung CC A 10-year analysis of thyrotoxic periodic paralysis in 135 patients: focus on symptomatology and precipitants. Eur J Endocrinol 2013;169(5):529\u2013536. doi:10.1530\/EJE-13-0381.","journal-title":"Eur J Endocrinol"},{"issue":"9684","key":"e_1_3_1_10_2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0140-6736(09)60507-9","article-title":"Hyperparathyroidism","volume":"374","author":"Fraser WD","year":"2009","unstructured":"Fraser WD. Hyperparathyroidism. Lancet 2009;374(9684):145\u2013158. doi:10.1016\/S0140-6736(09)60507-9.","journal-title":"Lancet"},{"issue":"2","key":"e_1_3_1_11_2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11926-002-0014-0","article-title":"Rheumatic manifestations of primary hyperparathyroidism and parathyroid hormone therapy","volume":"4","author":"Rubin MR","year":"2002","unstructured":"Rubin MR Silverberg SJ. Rheumatic manifestations of primary hyperparathyroidism and parathyroid hormone therapy. Curr Rheumatol Rep 2002;4(2):179\u2013185. doi:10.1007\/s11926-002-0014-0.","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"e_1_3_1_12_2","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.amjsurg.2008.08.017","article-title":"Total parathyroidectomy without autotransplantation in dialysis patients and renal transplant recipients, long-term follow-up evaluation","volume":"198","author":"Drakopoulos S","year":"2009","unstructured":"Drakopoulos S Koukoulaki M Apostolou T Total parathyroidectomy without autotransplantation in dialysis patients and renal transplant recipients, long-term follow-up evaluation. Am J Surg 2009;198(2):178\u2013183. doi:10.1016\/j.amjsurg.2008.08.017.","journal-title":"Am J Surg"},{"issue":"12","key":"e_1_3_1_13_2","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1056\/NEJM199503233321207","article-title":"Cushing\u2019s syndrome","volume":"332","author":"Orth DN","year":"1995","unstructured":"Orth DN. Cushing\u2019s syndrome. N Engl J Med 1995;332(12):791\u2013803. doi:10.1056\/NEJM199503233321207.","journal-title":"N Engl J Med"},{"issue":"2","key":"e_1_3_1_14_2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1365-2265.1983.tb03198.x","article-title":"Corticosteroid myopathy: a clinical and pathological study","volume":"18","author":"Khaleeli AA","year":"1983","unstructured":"Khaleeli AA Edwards RH Gohil K Corticosteroid myopathy: a clinical and pathological study. Clin Endocrinol (Oxf) 1983;18(2):155\u2013166. doi:10.1111\/j.1365-2265.1983.tb03198.x.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"e_1_3_1_15_2","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1212\/WNL.25.7.638","article-title":"Neuromuscular complications of acromegaly","volume":"25","author":"Pickett JB","year":"1975","unstructured":"Pickett JB Layzer RB Levin SR Neuromuscular complications of acromegaly. Neurology 1975;25(7):638\u2013645. doi:10.1212\/WNL.25.7.638.","journal-title":"Neurology"},{"key":"e_1_3_1_16_2","first-page":"175029","article-title":"Diabetic myonecrosis: uncommon complications in common diseases","volume":"2014","author":"Sran S","year":"2014","unstructured":"Sran S Sran M Ferguson N Anand P. Diabetic myonecrosis: uncommon complications in common diseases. Case Rep Endocrinol 2014;2014:175029. doi:10.1155\/2014\/175029.","journal-title":"Case Rep Endocrinol"},{"issue":"6","key":"e_1_3_1_17_2","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1210\/jc.2009-2354","article-title":"Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society Clinical Practice Guideline","volume":"95","author":"Bhasin S","year":"2010","unstructured":"Bhasin S Cunningham GR Hayes FJ Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2010;95(6):2536\u20132559. doi:10.1210\/jc.2009-2354.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"e_1_3_1_18_2","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1111\/j.1468-1331.2008.02328.x","article-title":"Paraneoplastic neurological syndromes in patients with carcinoid","volume":"15","author":"Tschernatsch M","year":"2008","unstructured":"Tschernatsch M Dierkes C Gerriets T Paraneoplastic neurological syndromes in patients with carcinoid. Eur J Neurol 2008;15(12):1390\u20131394. doi:10.1111\/j.1468-1331.2008.02328.x.","journal-title":"Eur J Neurol"},{"issue":"7","key":"e_1_3_1_19_2","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/RLU.0b013e3181779374","article-title":"Intramuscular metastasis of carcinoid tumor: a rare manifestation","volume":"33","author":"Tiktinsky E","year":"2008","unstructured":"Tiktinsky E Horne T Agranovich S Lantsberg S. Intramuscular metastasis of carcinoid tumor: a rare manifestation. Clin Nucl Med 2008;33(7):484\u2013485. doi:10.1097\/RLU.0b013e3181779374.","journal-title":"Clin Nucl Med"},{"issue":"11","key":"e_1_3_1_20_2","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1007\/s00134-007-0772-2","article-title":"Neuromuscular dysfunction acquired in critical illness: a systematic review","volume":"33","author":"Stevens RD","year":"2007","unstructured":"Stevens RD Dowdy DW Michaels RK Neuromuscular dysfunction acquired in critical illness: a systematic review. Intensive Care Med 2007;33(11):1876\u20131891. doi:10.1007\/s00134-007-0772-2.","journal-title":"Intensive Care Med"},{"issue":"3","key":"e_1_3_1_21_2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1164\/rccm.201205-0954SO","article-title":"Intensive care unit-acquired weakness: clinical phenotypes and molecular mechanisms","volume":"187","author":"Batt J","year":"2013","unstructured":"Batt J dos Santos CC Cameron JI Herridge MS. Intensive care unit-acquired weakness: clinical phenotypes and molecular mechanisms. Am J Respir Crit Care Med 2013;187(3):238\u2013246. doi:10.1164\/rccm.201205-0954SO.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"e_1_3_1_22_2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/mus.20304","article-title":"Neuromuscular manifestations of critical illness","volume":"32","author":"Bolton CF","year":"2005","unstructured":"Bolton CF. Neuromuscular manifestations of critical illness. Muscle Nerve 2005;32(2):140\u2013163. doi:10.1002\/mus.20304.","journal-title":"Muscle Nerve"},{"issue":"6","key":"e_1_3_1_23_2","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1046\/j.1365-2990.1998.00144.x","article-title":"Muscle fibre atrophy in critically ill patients is associated with the loss of myosin filaments and the presence of lysosomal enzymes and ubiquitin","volume":"24","author":"Helliwell TR","year":"1998","unstructured":"Helliwell TR Wilkinson A Griffiths RD Muscle fibre atrophy in critically ill patients is associated with the loss of myosin filaments and the presence of lysosomal enzymes and ubiquitin. Neuropathol Appl Neurobiol 1998;24(6):507\u2013517. doi:10.1046\/j.1365-2990.1998.00144.x.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"8","key":"e_1_3_1_24_2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s001340050669","article-title":"Patterns of neurophysiological abnormality in prolonged critical illness","volume":"24","author":"Coakley JH","year":"1998","unstructured":"Coakley JH Nagendran K Yarwood GD Patterns of neurophysiological abnormality in prolonged critical illness. Intensive Care Med 1998;24(8):801\u2013807. doi:10.1007\/s001340050669.","journal-title":"Intensive Care Med"},{"issue":"10","key":"e_1_3_1_25_2","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1474-4422(11)70178-8","article-title":"Critical illness polyneuropathy and myopathy: a major cause of muscle weakness and paralysis","volume":"10","author":"Latronico N","year":"2011","unstructured":"Latronico N Bolton CF. Critical illness polyneuropathy and myopathy: a major cause of muscle weakness and paralysis. Lancet Neurol 2011;10(10):931\u2013941. doi:10.1016\/S1474-4422(11)70178-8.","journal-title":"Lancet Neurol"},{"issue":"12","key":"e_1_3_1_26_2","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1007\/s001340050757","article-title":"Acquired neuromuscular disorders in critically ill patients: a systematic review. Groupe de Reflexion et d\u2019Etude sur les Neuromyopathies En Reanimation","volume":"24","author":"De Jonghe B","year":"1998","unstructured":"De Jonghe B Cook D Sharshar T Acquired neuromuscular disorders in critically ill patients: a systematic review. Groupe de Reflexion et d\u2019Etude sur les Neuromyopathies En Reanimation. Intensive Care Med 1998;24(12):1242\u20131250. doi:10.1007\/s001340050757.","journal-title":"Intensive Care Med"},{"issue":"8","key":"e_1_3_1_27_2","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1056\/NEJM199208203270804","article-title":"Persistent paralysis in critically ill patients after long-term administration of vecuronium","volume":"327","author":"Segredo V","year":"1992","unstructured":"Segredo V Caldwell JE Matthay MA Persistent paralysis in critically ill patients after long-term administration of vecuronium. N Engl J Med 1992;327(8):524\u2013528. doi:10.1056\/NEJM199208203270804.","journal-title":"N Engl J Med"},{"issue":"1","key":"e_1_3_1_28_2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00134-008-1304-4","article-title":"Intensive care unit-acquired neuromyopathy and corticosteroids in survivors of persistent ARDS","volume":"35","author":"Hough CL","year":"2009","unstructured":"Hough CL Steinberg KP Taylor Thompson B Intensive care unit-acquired neuromyopathy and corticosteroids in survivors of persistent ARDS. Intensive Care Med 2009;35(1):63\u201368. doi:10.1007\/s00134-008-1304-4.","journal-title":"Intensive Care Med"},{"issue":"12","key":"e_1_3_1_29_2","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1005372","article-title":"Neuromuscular blockers in early acute respiratory distress syndrome","volume":"363","author":"Papazian L","year":"2010","unstructured":"Papazian L Forel JM Gacouin A Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med 2010;363(12):1107\u20131116. doi:10.1056\/NEJMoa1005372.","journal-title":"N Engl J Med"},{"issue":"14","key":"e_1_3_1_30_2","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1011802","article-title":"Canadian Critical Care Trials Group. Functional disability 5 years after acute respiratory distress syndrome","volume":"364","author":"Herridge MS","year":"2011","unstructured":"Herridge MS Tansey CM Matt\u00e9 A Canadian Critical Care Trials Group. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med 2011;364(14):1293\u20131304. doi:10.1056\/NEJMoa1011802.","journal-title":"N Engl J Med"},{"issue":"9","key":"e_1_3_1_31_2","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1097\/CCM.0b013e3181a38937","article-title":"Early exercise in critically ill patients enhances short-term functional recovery","volume":"37","author":"Burtin C","year":"2009","unstructured":"Burtin C Clerckx B Robbeets C Early exercise in critically ill patients enhances short-term functional recovery. Crit Care Med 2009;37(9):2499\u20132505. doi:10.1097\/CCM.0b013e3181a38937.","journal-title":"Crit Care Med"},{"issue":"9","key":"e_1_3_1_32_2","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1345\/aph.10228","article-title":"Rhabdomyolysis and HMG-CoA reductase inhibitors","volume":"35","author":"Omar MA","year":"2001","unstructured":"Omar MA Wilson JP Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001;35(9):1096\u20131107. doi:10.1345\/aph.10228.","journal-title":"Ann Pharmacother"},{"issue":"7","key":"e_1_3_1_33_2","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1185\/03007995.2012.702102","article-title":"Myopathy during statin therapy in the daily practice of an outpatient cardiology clinic: prevalence, predictors and relation with vitamin D","volume":"28","author":"Riphagen IJ","year":"2012","unstructured":"Riphagen IJ van der Veer E Muskiet FA DeJongste MJ. Myopathy during statin therapy in the daily practice of an outpatient cardiology clinic: prevalence, predictors and relation with vitamin D. Curr Med Res Opin 2012;28(7):1247\u20131252. doi:10.1185\/03007995.2012.702102.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"e_1_3_1_34_2","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clpt.2006.06.010","article-title":"SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin","volume":"80","author":"Niemi M","year":"2006","unstructured":"Niemi M Pasanen MK Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther 2006;80(4):356\u2013366. doi:10.1016\/j.clpt.2006.06.010.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"e_1_3_1_35_2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejim.2015.01.002","article-title":"Risk identification and possible countermeasures for muscle adverse effects during statin therapy","volume":"26","author":"Magni P","year":"2015","unstructured":"Magni P Macchi C Morlotti B Risk identification and possible countermeasures for muscle adverse effects during statin therapy. Eur J Intern Med 2015;26(2):82\u201388. doi:10.1016\/j.ejim.2015.01.002.","journal-title":"Eur J Intern Med"},{"issue":"2","key":"e_1_3_1_36_2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jacl.2012.06.006","article-title":"Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting","volume":"7","author":"Cziraky MJ","year":"2013","unstructured":"Cziraky MJ Willey VJ McKenney JM Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. J Clin Lipidol 2013;7(2):102\u2013108. doi:10.1016\/j.jacl.2012.06.006.","journal-title":"J Clin Lipidol"},{"issue":"1","key":"e_1_3_1_37_2","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.amjcard.2004.08.076","article-title":"Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin","volume":"95","author":"Jones PH","year":"2005","unstructured":"Jones PH Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005;95(1):120\u2013122. doi:10.1016\/j.amjcard.2004.08.076.","journal-title":"Am J Cardiol"},{"issue":"5","key":"e_1_3_1_38_2","first-page":"e212","article-title":"Statin myopathy: a lipid clinic experience on the tolerability of statin rechallenge","volume":"30","author":"Fung EC","year":"2012","unstructured":"Fung EC Crook MA. Statin myopathy: a lipid clinic experience on the tolerability of statin rechallenge. Cardiovasc Ther 2012;30(5):e212\u2013e218. doi:10.1111\/j.1755-5922.2011.00267.x.","journal-title":"Cardiovasc Ther"},{"issue":"5","key":"e_1_3_1_39_2","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1111\/j.1468-1331.2012.03678.x","article-title":"Amiodarone-associated neuromyopathy: a report of four cases","volume":"19","author":"Flanagan EP","year":"2012","unstructured":"Flanagan EP Harper CM St Louis EK Amiodarone-associated neuromyopathy: a report of four cases. Eur J Neurol 2012;19(5):e50\u2013e51. doi:10.1111\/j.1468-1331.2012.03678.x.","journal-title":"Eur J Neurol"},{"issue":"2","key":"e_1_3_1_40_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000134943","article-title":"Mechanisms of zidovudine-induced mitochondrial toxicity and myopathy","volume":"82","author":"Scruggs ER","year":"2008","unstructured":"Scruggs ER Dirks Naylor AJ. Mechanisms of zidovudine-induced mitochondrial toxicity and myopathy. Pharmacology 2008;82(2):83\u201388. doi:10.1159\/000134943.","journal-title":"Pharmacology"},{"issue":"2","key":"e_1_3_1_41_2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jhep.2010.03.006","article-title":"Clinical, biochemical, and pathological characteristics of clevudine-associated myopathy","volume":"53","author":"Tak WY","year":"2010","unstructured":"Tak WY Park SY Cho CM Clinical, biochemical, and pathological characteristics of clevudine-associated myopathy. J Hepatol 2010;53(2):261\u2013266. doi:10.1016\/j.jhep.2010.03.006.","journal-title":"J Hepatol"},{"issue":"3","key":"e_1_3_1_42_2","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1002\/mus.21091","article-title":"Severe hydroxychloroquine myopathy","volume":"38","author":"Abdel-Hamid H","year":"2008","unstructured":"Abdel-Hamid H Oddis CV Lacomis D. Severe hydroxychloroquine myopathy. Muscle Nerve 2008;38(3):1206\u20131210. doi:10.1002\/mus.21091.","journal-title":"Muscle Nerve"},{"issue":"2","key":"e_1_3_1_43_2","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s004010100434","article-title":"Colchicine myopathy: a vacuolar myopathy with selective type I muscle fiber involvement. An immunohistochemical and electron microscopic study of two cases","volume":"103","author":"Fernandez C","year":"2002","unstructured":"Fernandez C Figarealla-Branger D Alla P Colchicine myopathy: a vacuolar myopathy with selective type I muscle fiber involvement. An immunohistochemical and electron microscopic study of two cases. Acta Neuropathol 2002;103(2):100\u2013106. doi:10.1007\/s004010100434.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"e_1_3_1_44_2","first-page":"363","article-title":"Alcohol-associated rhabdomyolysis: ethanol induction of cytochrome P450 may potentiate myotoxicity","volume":"21","author":"Riggs JE","year":"1998","unstructured":"Riggs JE. Alcohol-associated rhabdomyolysis: ethanol induction of cytochrome P450 may potentiate myotoxicity. Clin Neuropharmacol 1998;21(6):363\u2013364.","journal-title":"Clin Neuropharmacol"}],"container-title":["Continuum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00132979-201612000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T13:58:15Z","timestamp":1752155895000},"score":1,"resource":{"primary":{"URL":"https:\/\/continuum.aan.com\/doi\/10.1212\/CON.0000000000000407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.1212\/CON.0000000000000407"],"URL":"https:\/\/doi.org\/10.1212\/con.0000000000000407","relation":{},"ISSN":["1080-2371","1538-6899"],"issn-type":[{"value":"1080-2371","type":"print"},{"value":"1538-6899","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}